Viewing Study NCT01163357

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 6:38 PM
Ignite Modification Date: 2025-12-27 @ 6:37 AM
Study NCT ID: NCT01163357
Status: COMPLETED
Last Update Posted: 2025-03-26
First Post: 2010-07-14
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
Sponsor: City of Hope Medical Center
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Autologous Hematopoietic Stem Cell Transplant Recipient View
None Loss of Chromosome 17p View
None Plasma Cell Leukemia View
None Recurrent Plasma Cell Myeloma View
None Refractory Plasma Cell Myeloma View
Keywords: